Gland Pharma Ltd

Gland Pharma has appointed Wriddhee Maitra as Vice-President (Human Resources), a Senior Management Personnel of the Company with effect from 10 March 2025.Powered by Capital Market - Live

Gland Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1663.3, up 2.05% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.03% on the day, quoting at 22550.8. The Sensex is at 74315, down 0.03%. Gland Pharma Ltd has gained around 12.55% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 5.76% in last one month and is currently quoting at 20423.35, down 0.03% on the day. The volume in the stock stood at 95455 shares today, compared to the daily average of 2.64 lakh shares in last one month.The PE of the stock is 23.95 based on TTM earnings ending December 24.Powered by Capital Market - Live

Gland Pharma has allotted 4,700 equity shares under ESOP on 26 February 2025. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 164,756,423/- comprising 164,756,423 equity shares of face value Re.1/- each. Powered by Capital Market - Live

Gland Pharma announced that the United States Food and Drug Administration (US FDA) has conducted a Pre-approval inspection (PAI) for Sterile APIs at the Company's Facility at JNPC, Visakhapatnam between 19 February 2025 and 25 February 2025. The said inspection was concluded with THREE (3) Form 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the US FDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity. Powered by Capital Market - Live

The inspection was conducted from 19 February 2025 to 25 February 2025. At the conclusion of the inspection, the USFDA issued a Form 483 with three observations. The company stated that these observations are procedural in nature, and it plans to submit corrective and preventive actions to the USFDA within the required time frame. The company further clarified that the observations are not repeated and are unrelated to any data integrity concerns. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. Gland Pharma's consolidated net profit increased 6.67% to Rs 204.70 crore despite 10.42% decline in revenue from operations to Rs 1,384.1 crore in Q3 FY25 over Q3 FY25. The scrip rallied 4.62% to settle at Rs 1,595.50 on the BSE. Powered by Capital Market - Live

Net profit of Gland Pharma rose 6.69% to Rs 204.69 crore in the quarter ended December 2024 as against Rs 191.86 crore during the previous quarter ended December 2023. Sales declined 10.43% to Rs 1384.05 crore in the quarter ended December 2024 as against Rs 1545.16 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1384.051545.16 -10 OPM %26.0123.06 - PBDT395.63388.50 2 PBT299.30283.16 6 NP204.69191.86 7 Powered by Capital Market - Live

Profit before tax (PBT) stood at Rs 299.30 crore in Q3 FY25, up 5.68%, compared with Rs 283.20 crore in the third quarter of FY24. For Q3 of FY25, EBITDA was Rs 360 crore, registering a growth of 1.20% YoY. EBITDA margin improved from 23% to 26% during the quarter. Revenue from the US market stood at Rs 729.30 crore (down 11.23% YoY), revenue from Europe was at Rs 264.60 crore (down 18.60% YoY), Canada, Australia, and New Zealand stood at Rs 45.90 crore (up 20.15% YoY), while revenue from India was at Rs 56.20 crore and the rest of the world was at Rs 288.10 crore during the period under review. Total capex incurred during the quarter was Rs 137.90 crore. R&D expenses stood at Rs 43.70 crore in Q2 of FY25 (4.3% of revenue). Cenexi's gross profit shed 14.25% YoY to Rs 285.60 crore, and revenue from operations decreased 16.26% YoY to Rs 371.70 crore during the quarter. During the quarter, the company launched 13 new molecules, including chlorpromazine, dexamethasone, phenylephrine, phytonadione, and diphenhydramine. Additionally, the company received Establishment Inspection Reports (EIRs) from the USFDA for its Dundigal and Pashamylaram facilities in Hyderabad, India, marking the successful closure of recent USFDA inspections. On outlook front, the company said Cenexi maintains its goal of achieving a positive EBITDA for the next fiscal year, driven by an increase in revenue above the '200 million threshold. Srinivas Sadu, Executive Chairman of Gland Pharma, said, 'Our Q3 FY25 revenue was at Rs 13,841 million with an EBITDA of Rs 3,600 million, resulting in a 26% EBITDA margin. Notably, our base business EBITDA margin saw a significant improvement of 500 basis points, reaching 39%. We are also excited about the progress of our strategic biologics CDMO collaborations with some of the leading companies in this space. These partnerships open doors to exciting opportunities in the rapidly growing biologics CDMO segment and are expected to generate incremental revenue starting next financial year. Furthermore, the recent conclusion of the USFDA inspections at our Dundigal and Pashamylaram facilities underscores our unwavering commitment to quality and regulatory compliance. We remain focused on driving long-term value creation through strategic partnerships, innovation, and continued investments in new products and technologies.' Shyamakant Giri, CFO, Gland Pharma, said, 'I am honored and excited to lead Gland Pharma as its new CEO. Building on the company's strong foundation, my focus will be on enhancing operational excellence in our base business, ensuring Cenexi's successful turnaround, identifying and pursuing new growth opportunities, and further solidifying our position as a leader in the CDMO space, particularly in biologics and complex injectables. I believe that by fostering a culture of innovation, collaboration, and customercentricity, we can achieve sustainable growth and create long-term value for all our stakeholders.' Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. Shares of Gland Pharma slipped 5.41% to currently trade at Rs 1,438 on the BSE.Powered by Capital Market - Live

Gland Pharma announced that following the Inspection for Good Manufacturing Practices (GMP) by US FDA at the Company's Pashamylaram Facility at Hyderabad between 25 July, 2024 and 02 August, 2024; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.Powered by Capital Market - Live

The Pashamylaram facility received an EIR, which indicates closure of the inspection, Gland Pharma said in a filing. The USFDA inspected the facility between 25 July 2024 and 2 August 2024 for good manufacturing practices (GMP) and issued three Form 483 observations. These observations were procedural in nature. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. On a consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. The scrip rose 0.10% to settle at Rs 1,678.95 on Friday, 18 January 2025. Powered by Capital Market - Live

Gland Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1699.55, up 1.41% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.43% on the day, quoting at 23211.05. The Sensex is at 76656.14, down 0.5%. Gland Pharma Ltd has slipped around 3.65% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has slipped around 1.43% in last one month and is currently quoting at 21909.75, up 0.39% on the day. The volume in the stock stood at 62727 shares today, compared to the daily average of 2.35 lakh shares in last one month.The PE of the stock is 25.06 based on TTM earnings ending September 24.Powered by Capital Market - Live